卵巢癌患者血清人激肽释放酶10的检测及其临床意义  

Detection of serum human kallikrein 10 in patients with ovarian cancer and its clinical significance

作　　者：王翠翠[1] 张晓霞[1] 王丽娜[1] 许淑芬[2] 欧健[1] 田海涵 

机构地区：[1]吉林大学第一医院妇产科,吉林长春130021 [2]吉林大学第一医院中心实验室,吉林长春130021 [3]内蒙古自治区通辽市红星医院,内蒙古通辽028000

出　　处：《吉林大学学报（医学版）》2010年第3期540-542,共3页Journal of Jilin University：Medicine Edition

基　　金：吉林省教育厅基金资助课题(吉教科合字[2005]第132号)

摘　　要：目的:检测卵巢癌患者及其对照组血清人激肽释放酶10(hk10)水平,探讨血清hk10在卵巢癌诊断中的临床意义。方法:ELISA法检测卵巢癌组(n=50)、卵巢良性肿瘤组(n=20)、妇科良性疾病组(CA125增高,n=26)、妇科其他癌症组(n=18)患者及健康对照组(n=36)血清hk10水平。结果:卵巢癌组hk10水平为(15.6±9.23)μg·L-1,阳性率为88.89%;卵巢良性肿瘤组hk10水平和阳性率分别为(6.60±2.65)μg·L-1和10.00%;CA125值增高的妇科良性疾病组血清hk10水平和阳性率分别为(6.92±2.97)μg·L-1和15.38%;妇科其他癌症组hk10水平和阳性率分别为(6.11±2.42)μg·L-1和11.11%;对照组hk10水平为(6.00±2.26)μg·L-1,阳性率为11.11%;卵巢癌组血清hk10水平和阳性率均显著高于其他各组(P<0.01)。Ⅲ/Ⅳ期卵巢癌组血清hk10水平和阳性率分别为(18.29±9.74)μg·L-1和94.44%,显著高于Ⅰ/Ⅱ期卵巢癌组的(9.87±4.04)μg·L-1和75.00%(P<0.01)。卵巢癌组术后血清hk10水平为(13.83±1.56)μg·L-1,低于术前的hk10水平。结论:卵巢癌组血清hk10水平显著增高,特异性优于CA125,其有望成为卵巢癌新的肿瘤标志物。Objective To detect the serum human kallikrein 10 （hk10） expression in patients with ovarian cancer and control groups,and investigate the clinical significance of hk10 in the diagnosis of ovarian cancer. Methods Enzyme-linked immunoassay （ELISA）mothod was used to detect the hk10 levels in serum in ovarian cancer group（n=50）,benign ovarian tumor group（n=20）,benign gynecological disease （higher CA125 values,n=26）,other malignant gynecological cancer group（n=18） and healthy controls（n=36）. Results The level of serum hk10 in the ovarian cancer group was（15.60±9.23） μg·L-1 and the positive rate was 88.89%,in benign ovarian tumor group they were（6.60±2.65） μg·L-1 and 10.00%;in other malignant gynecological cancer group they were（6.11±2.42） μg·L-1 and 11.11%,in healthy control group they were（6.00±2.26） μg·L-1 and 11.11%,the level of serum hk10 and the positive rate in ovarian cancer group were higher than those in other groups（P0.01）.The level of serum hk10 and the positive rate in stage Ⅲ/Ⅳ ovarian cancer group were（18.29±9.74） μg·L-1 and 94.44%,they were significantly higher than those in stage Ⅰ / Ⅱ ovarian cancer group（9.87 μg·L-1±4.04 μg·L-1 and 75.00%）（P0.01）.The level of serum hK10 in patients with ovarian cancer after operation was （13.83±1.56） μg·L-1 which was lower than before operation. Conclusion The serum hk10 level is significantly increased in ovarian cancer group,its specificity was higher than CA125. hk10 is expected to become a new marker in ovarian cancer.

关 键 词：人血清激肽释放酶10 卵巢肿瘤 CA125 

分 类 号：R737.31[医药卫生—肿瘤]